Aligos Therapeutics is a biopharmaceutical company focused on developing innovative therapies for viral and liver diseases. Their lead drug candidate, ALG-010133, is currently in Phase Ib clinical trials for the treatment of chronic hepatitis B, while their ALG-000184 capsid assembly modulator is in Phase I clinical trials to treat the same condition. Additionally, the company has entered into various license and collaboration agreements to further their research and product development efforts.